Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children

Journal of Child and Adolescent Psychopharmacology

Volumn 11, Issue 4, 2001, Pages 435-440

  Cohen, Louise Glassner ^a   Biederman, Joseph ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; RISPERIDONE; SEROTONIN 2A RECEPTOR;

CASE REPORT; CHILD; CHILD DEVELOPMENT; CHILD GROWTH; CONFERENCE PAPER; DRUG MECHANISM; DRUG TOLERABILITY; HUMAN; HYPERPROLACTINEMIA; MALE; MANIC DEPRESSIVE PSYCHOSIS; PROLACTINOMA; PSYCHOSIS; SHORT STATURE;

EID: 0035704770     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/104454601317261618     Document Type: Conference Paper

References (35)

1. Neuroendocrine regulation and diseases of the anterior pituitary
2. Clozapine and risperidone in chronic schizophrenia: Effects on symptoms, parkinsonian side effects, and neuroendocrine response
3. Prolactin levels in premenopausal women treated with risperidone compared with those of women treated with typical neuroleptics
4. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment
5. Prolactinomas in adolescents: Persistent bone loss after 2 years of prolactin normalization
6. Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up
7. Risperidone-induced prolactin elevations in premenopausal women with schizophrenia
8. Neuroleptic-induced hyperprolactinemia
9. Bromocriptine in DRUGDEX
10. DRUGDEX System: Cabergoline in DRUGDEX
11. Peripubertal prolactinomas: Clinical presentation and long-term outcome with different therapeutic approaches
12. Risperidone treatment for juvenile bipolar disorder: A retrospective chart review
13. Dimitriadis A: Osteopenia in children and adolescents with hyperprolactinemia
14. Hyperprolactinemia in antipsychotic-treated patients
15. Pharmacokinetics of the novel antipsychotic agent risperidone and the protactin response in healthy subjects
16. Delayed puberty associated with hyperprolactinemia caused by pituitary microadenoma
17. Risperidone and associated amenorrhea: A report of 5 cases
18. Prolactin levels and adverse events in patients treated with risperidone
19. Clinical presentation of hyperprolactinemia
20. Dopamine receptor responsivity in schizophrenic patients before and after switch from haloperidol to risperidone
21. Gonadal axis hormones in male schizophrenic patients during treatment with haloperidol and after switch to risperidone
22. Pediatric pituitary adenomas
23. Medical treatment of prolactinomas
24. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT 2A receptor occupancy in schizophrenic patients
25. Prolactin and antipsychotic medications: Mechanism of action
26. Risperidone in the treatment of patients with chronic schizophrenia: A multi-national, multi-centre, doubleblind, parallel-group study versus haloperidol
27. Risperidone-induced galactorrhea associated with a prolactin elevation
28. Carbergoline: A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinemia and inhibition of lactation
29. Atypical antipsychotics: Are some more atypical then others?
30. Prolactogenic effects of risperidone in male patients - A preliminary study
31. Prolactin-secreting macroadenomas in adolescents. Response to bromocriptine therapy
32. Cabergoline in the treatment of hyperprolactinemia: A study in 455 patients
33. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea
34. Prolactin disorders